Ampio provides update on clinical trials for Ampion treatment of COVID-19
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced an update on the launch of a new global clinical trial for intravenous treatment of COVID-19 with Ampion and provided updates... Read More
Tuesday January 5, 2021 0 comments
Ampio's Phase I study for inhaled Ampion advances to completing enrollment of COVID-19 patients
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced its AP-014 Phase I inhaled Ampion clinical study in COVID-19 patients is proceeding to full open enrollment following... Read More
Friday December 4, 2020 0 comments
Ampio's Phase I study for Inhaled Ampion advances to 2nd group of COVID-19 patients with lung distress
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced the second group in the Phase I inhaled Ampionclinical study is being treated following clearance by the Safety Monitoring... Read More
Wednesday November 11, 2020 0 comments
Ampio begins Phase 1 clinical trial of inhaled Ampion for COVID-19
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced it hasbegun recruiting and enrolling patients in a Phase Imulti-center, randomized, controlled trial for a total of 40... Read More
Thursday October 29, 2020 0 comments
Ampio Pharmaceutical's FDA application for Ampion clinical study to treat COVID-19 ARDS on TV
ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE American: AMPE) announced it was featured on aFOXTV segment titled, "Englewoodpharmaceutical company looking to treat COVID-19 patients with... Read More
Friday April 3, 2020 0 comments
Ampio Pharmaceuticals appoints Dan Stokely CFO
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a development stage biopharmaceutical company focused on the discovery and development of a novel therapy aimed at treating common... Read More
Thursday July 11, 2019 0 comments
Ampio: Ampion achieves major decrease in patient osteoarthritis knee pain
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) reported that the Phase 3 clinical trial of Ampion met its primary endpoint with 71% of Ampion treated patients meeting the... Read More
Friday December 15, 2017 0 comments
Ampio Pharmaceuticals announces allowance of composition and methods patent for Ampion
ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE MKT: AMPE) today announced the allowance of an important composition and methods patent in the U.S. complimenting a series of patents on Ampion... Read More
Tuesday August 8, 2017 0 comments
IN Sponsors
Browse
Entrepreneurial by Nature
